About half
Of the small-molecule drugs approved since 1981 are natural products or are built on one.
Vrisko Biosciences
Vrisko-1 is our foundation model for traditional medicine discovery. It predicts structures, designs small molecules and designs proteins.
Public release March 2027.
Why start with traditional medicine
About half
Of the small-molecule drugs approved since 1981 are natural products or are built on one.
More than 100,000
Lives a year saved in Africa alone by artemisinin, a malaria drug that came out of traditional herbal medicine.
30 years
Paclitaxel, from a bark sample in 1962 to FDA approval in 1992.
Sources include Stone et al., 2022; Nobel Assembly, 2015; National Cancer Institute.
The Vrisko discovery platform
Vrisko-1 predicts how the compounds in a medicine fit a disease target, then designs small molecules and proteins from what it finds.
A confidence score with every structure.
Bioassays on fractions, pure compounds and new designs, chosen by what Vrisko-1 predicts. Activity gets traced to a single molecule, not a mixture.
Results tied to a compound.
Every prediction, design and result, failures included, goes back into one dataset for the next round.
Every result kept.
Every result goes back into the next round
Vrisko-1
Predicts the 3D structure of a disease target and how a compound from a traditional medicine fits it.
A confidence score with every structure.
Designs new molecules from compounds that work: more potent, simpler to make, easier for the body to handle.
Nothing is called a candidate until it is tested.
Designs proteins that bind a disease target.
Every design is tested for activity before we report it.
Public release: March 2027 · Early access for researchers who want to run it themselves.
Development status
Training data
In progress
Vrisko-1, first version
In progress
Researcher access
Coming soon
Last updated 17 November 2026
Early access
We're building Vrisko-1 for researchers to use directly. Leave your details and tell us what you'd try. We'll write when access opens.
Model access for researchers: coming soon
Responsible sourcing
We don't collect anything without the permits the law requires and the informed consent of the people who hold the knowledge.
Access, use and benefit-sharing are agreed in writing before any material moves, and the other side keeps a copy.
What we learn goes back to the people who made it possible, in a form they can use, before it goes anywhere else.
Partnerships
Partner with us.
Some teams bring us a target and we build a project around it. Others have a traditional medicine they want profiled and tested, a molecule or protein they want designed, data sitting unused, or a need for lab capacity. Tell us what you're trying to find out.